Objectives: to explore the experience of treatment decision-making (TDM) amongst men diagnosed with stage 1-3 prostate cancer. Methods: Mixed-methods study incorporating UK wide cross-sectional postal survey of men 18-42 months post-diagnosis and semi-structured interviews with a subsample (n=97), including men who received both radical treatments and active surveillance. Interview data was analysed using a Framework approach. Findings: within the context of TDM, ‘drivers’ included men’s preferences for decision-making responsibility or clinical direction, relative treatment intrusiveness or desire for excision, and work, personal and social life priorities; ‘facilitators’ were mechanisms such as shared decision-making utilised by clinician...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
Objective: Clinical options for managing non-metastatic prostate cancer (PCa) vary. Each option has ...
Objectives: To explore experiences of treatment decision-making (TDM) amongst men diagnosed with sta...
Objectives. To explore the experience of treatment decision-making (TDM) amongst men diagnosed with ...
Background: The incidence of prostate continues to increase but due to the management strategies ava...
Prostate cancer is the most commonly diagnosed malignancy among US men. Men diagnosed with LPC, or c...
Objective To describe the decision-making processes used by men diagnosed with localized prostate ca...
Objective To describe the decision-making processes used by men diagnosed with localized prostate ca...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
Most men with low-risk prostate cancer have several treatment options. Since there is no clear evide...
For men with newly diagnosed prostate cancer the decisions about treatment options are complex and d...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
Objective: Clinical options for managing non-metastatic prostate cancer (PCa) vary. Each option has ...
Objectives: To explore experiences of treatment decision-making (TDM) amongst men diagnosed with sta...
Objectives. To explore the experience of treatment decision-making (TDM) amongst men diagnosed with ...
Background: The incidence of prostate continues to increase but due to the management strategies ava...
Prostate cancer is the most commonly diagnosed malignancy among US men. Men diagnosed with LPC, or c...
Objective To describe the decision-making processes used by men diagnosed with localized prostate ca...
Objective To describe the decision-making processes used by men diagnosed with localized prostate ca...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
Most men with low-risk prostate cancer have several treatment options. Since there is no clear evide...
For men with newly diagnosed prostate cancer the decisions about treatment options are complex and d...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
International audiencePurposeIn diseases where there is no real consensus regarding treatment modali...
Objective: Clinical options for managing non-metastatic prostate cancer (PCa) vary. Each option has ...